Abstract：Objective To observe the clinical efficacy of somatostatin analogists combined with everolimus in the treatment of pancreatic neuroendocrine tumors. Methods A total of 54 patients with pancreatic neuroendocrine tumor admitted to our hospital were selected and divided into observation group（n=27）and control group（n=27）according to random number table method.The control group was treated with somatostatin analogue,and the observation group was treated with somatostatin analogue combined with everolimus.The treatment effect,time to progression,recurrence rate 1-3 years after operation,serum CgA level and the incidence of related complications were compared between the two groups. Results The time to progression in the observation group was significantly longer than that in the control group,and the 1-3 years recurrence rate was significantly lower than that in the control group（P<0.05）.After 3 months of treatment,the serum CGA level in the observation group was significantly lower than that in the control group（P<0.05）.However,the incidence of adverse reactions（mainly oral inflammation）in the observation group was significantly higher than that in the control group（P<0.05）. Conclusion The clinical efficacy of somatostatin analogue combined with everolimus in the treatment of pancreatic neuroendocrine tumors is better than that of somatostatin analogue alone,which can prolong the time to progression and reduce disease recurrence in patients.However,the incidence of adverse reactions in patients taking everolimus is higher,which needs to be solved clinically.
2022, Vol. 42 
